Michal Jarzab - Publications

Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study.

Journal: The oncologist

Published: May 07, 2026

Association of PD-L1 combined positive score with disease control and response kinetics with first-line pembrolizumab-based therapy in metastatic triple-negative breast cancer: results from routine clinical practice in Poland.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: March 25, 2026

Real-world outcomes of sacituzumab govitecan in patients with pretreated triple-negative breast cancer and brain metastases: data from CEBCC-102 study.

Journal: Journal of neuro-oncology

Published: December 03, 2025

18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography Guided Stereotactic Body Radiation Therapy in Advanced Breast Cancer Patients Treated WithCyclin-Dependent Kinase 4/6 Inhibitors.

Journal: Advances in radiation oncology

Published: December 02, 2025

Effectiveness of sacituzumab govitecan in metastatic triple-negative breast cancer: a real-world retrospective cohort study from Central Europe.

Journal: The oncologist

Published: November 23, 2025

Impact of Germline BRCA1/2 Mutations on Clinical Outcomes in Metastatic Triple-Negative Breast Cancer Patients Treated with Sacituzumab Govitecan-An International CEBCC Study from Poland, the Czech Republic and Slovakia.

Journal: Oncology research

Published: November 19, 2025

Combined positive score status in metastatic triple-negative breast cancer patients treated with sacituzumab govitecan: associated clinical characteristics and testing patterns in a Central European cohort.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 17, 2025